---
annotation-target: blood.2022018003.pdf
---


>%%
>```annotation-json
>{"created":"2022-09-16T08:16:59.626Z","updated":"2022-09-16T08:16:59.626Z","document":{"title":"blood.2022018003.pdf","link":[{"href":"urn:x-pdf:0f743528fbd87fed6d141af32defce56"},{"href":"vault:/hematology-theroy/papers/20220916/blood.2022018003.pdf"}],"documentFingerprint":"0f743528fbd87fed6d141af32defce56"},"uri":"vault:/hematology-theroy/papers/20220916/blood.2022018003.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220916/blood.2022018003.pdf","selector":[{"type":"TextPositionSelector","start":840,"end":880},{"type":"TextQuoteSelector","exact":"Introduction to the How I Treat Series o","prefix":"df by guest on 16 September 2022","suffix":"n “How I Manage High-Risk Patien"}]}]}
>```
>%%
>*%%PREFIX%%df by guest on 16 September 2022%%HIGHLIGHT%% ==Introduction to the How I Treat Series o== %%POSTFIX%%n “How I Manage High-Risk Patien*
>%%LINK%%[[#^u1jx74mphu|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^u1jx74mphu


>%%
>```annotation-json
>{"created":"2022-09-16T08:17:27.893Z","updated":"2022-09-16T08:17:27.893Z","document":{"title":"blood.2022018003.pdf","link":[{"href":"urn:x-pdf:0f743528fbd87fed6d141af32defce56"},{"href":"vault:/hematology-theroy/papers/20220916/blood.2022018003.pdf"}],"documentFingerprint":"0f743528fbd87fed6d141af32defce56"},"uri":"vault:/hematology-theroy/papers/20220916/blood.2022018003.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220916/blood.2022018003.pdf","selector":[{"type":"TextPositionSelector","start":2083,"end":2163},{"type":"TextQuoteSelector","exact":"Relapse of high-risk leukemia after allo-HCT remains a major clinical challenge.","prefix":"vation in high-risk patients”   ","suffix":" The article on the use of pre-e"}]}]}
>```
>%%
>*%%PREFIX%%vation in high-risk patients”%%HIGHLIGHT%% ==Relapse of high-risk leukemia after allo-HCT remains a major clinical challenge.== %%POSTFIX%%The article on the use of pre-e*
>%%LINK%%[[#^5fu3zsexplw|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^5fu3zsexplw


>%%
>```annotation-json
>{"created":"2022-09-16T08:18:06.865Z","updated":"2022-09-16T08:18:06.865Z","document":{"title":"blood.2022018003.pdf","link":[{"href":"urn:x-pdf:0f743528fbd87fed6d141af32defce56"},{"href":"vault:/hematology-theroy/papers/20220916/blood.2022018003.pdf"}],"documentFingerprint":"0f743528fbd87fed6d141af32defce56"},"uri":"vault:/hematology-theroy/papers/20220916/blood.2022018003.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220916/blood.2022018003.pdf","selector":[{"type":"TextPositionSelector","start":2301,"end":3214},{"type":"TextQuoteSelector","exact":" Response rates of relapsed acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) to donor lymphocytes (DLI) are low and the role of pre-emptive DLI  upon  detection  of  measurable  residual  disease  (MRD)  is  unclear  due  to  the  lack  of prospective  randomized  studies.  Biederstädt  and  Rezvani  discuss  the  challenges  of  MRD-triggered DLI treatment after allo-HCT, they outline novel approaches of post-allo-HCT cellular therapies, including the role of Chimeric Antigen Receptor (CAR)-redirected cellular therapy and T cell receptor (TCR) gene therapy. Additionally, a practical structure for the decision-making process whether to use preemptive cellular therapy or not for patients with high-risk leukemia is provided.  Besides cellular therapy-based approaches, drug-based maintenance therapy after allo-HCT has shown encouraging results in certain types of high-risk leukemias, ","prefix":"sed to prevent or treat relapse.","suffix":"which is the topic of the articl"}]}]}
>```
>%%
>*%%PREFIX%%sed to prevent or treat relapse.%%HIGHLIGHT%% ==Response rates of relapsed acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) to donor lymphocytes (DLI) are low and the role of pre-emptive DLI  upon  detection  of  measurable  residual  disease  (MRD)  is  unclear  due  to  the  lack  of prospective  randomized  studies.  Biederstädt  and  Rezvani  discuss  the  challenges  of  MRD-triggered DLI treatment after allo-HCT, they outline novel approaches of post-allo-HCT cellular therapies, including the role of Chimeric Antigen Receptor (CAR)-redirected cellular therapy and T cell receptor (TCR) gene therapy. Additionally, a practical structure for the decision-making process whether to use preemptive cellular therapy or not for patients with high-risk leukemia is provided.  Besides cellular therapy-based approaches, drug-based maintenance therapy after allo-HCT has shown encouraging results in certain types of high-risk leukemias,== %%POSTFIX%%which is the topic of the articl*
>%%LINK%%[[#^0hg6p01jwlp|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^0hg6p01jwlp


>%%
>```annotation-json
>{"created":"2022-09-16T08:18:35.120Z","updated":"2022-09-16T08:18:35.120Z","document":{"title":"blood.2022018003.pdf","link":[{"href":"urn:x-pdf:0f743528fbd87fed6d141af32defce56"},{"href":"vault:/hematology-theroy/papers/20220916/blood.2022018003.pdf"}],"documentFingerprint":"0f743528fbd87fed6d141af32defce56"},"uri":"vault:/hematology-theroy/papers/20220916/blood.2022018003.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220916/blood.2022018003.pdf","selector":[{"type":"TextPositionSelector","start":3510,"end":3988},{"type":"TextQuoteSelector","exact":" This information may guide the decision on the use of maintenance therapy for the more selective treatment of patients at high risk of relapse while sparing other patients. The article connects common case scenarios with the currently available therapeutic agents including FLT3 inhibitors, isocitrate dehydrogenase (IDH) 1 and 2 inhibitors, BCL-2 inhibitors, BCR-ABL1 tyrosine kinase inhibitors and hypomethylating agents in the context of published data and ongoing studies. ","prefix":"ity of the conditioning regimen.","suffix":" Severe acute GVHD and related i"}]}]}
>```
>%%
>*%%PREFIX%%ity of the conditioning regimen.%%HIGHLIGHT%% ==This information may guide the decision on the use of maintenance therapy for the more selective treatment of patients at high risk of relapse while sparing other patients. The article connects common case scenarios with the currently available therapeutic agents including FLT3 inhibitors, isocitrate dehydrogenase (IDH) 1 and 2 inhibitors, BCL-2 inhibitors, BCR-ABL1 tyrosine kinase inhibitors and hypomethylating agents in the context of published data and ongoing studies.== %%POSTFIX%%Severe acute GVHD and related i*
>%%LINK%%[[#^41u00h9ux73|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^41u00h9ux73


>%%
>```annotation-json
>{"created":"2022-09-16T08:19:25.547Z","updated":"2022-09-16T08:19:25.547Z","document":{"title":"blood.2022018003.pdf","link":[{"href":"urn:x-pdf:0f743528fbd87fed6d141af32defce56"},{"href":"vault:/hematology-theroy/papers/20220916/blood.2022018003.pdf"}],"documentFingerprint":"0f743528fbd87fed6d141af32defce56"},"uri":"vault:/hematology-theroy/papers/20220916/blood.2022018003.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220916/blood.2022018003.pdf","selector":[{"type":"TextPositionSelector","start":4944,"end":5319},{"type":"TextQuoteSelector","exact":"Reactivation of viruses is one of the most common and life-threatening infectious complications after  allo-HCT.  Boeckh  and  colleges  discuss  the  role  of  pharmacological  or  immune intervention-based  prevention  for  herpes  simplex  virus,  varicella  zoster  virus,  and cytomegalovirus for high risk patients undergoing allo-HCT in light of recent clinical trials","prefix":" abatacept and JAK inhibitors.  ","suffix":". Using illustrative  clinical  "}]}]}
>```
>%%
>*%%PREFIX%%abatacept and JAK inhibitors.%%HIGHLIGHT%% ==Reactivation of viruses is one of the most common and life-threatening infectious complications after  allo-HCT.  Boeckh  and  colleges  discuss  the  role  of  pharmacological  or  immune intervention-based  prevention  for  herpes  simplex  virus,  varicella  zoster  virus,  and cytomegalovirus for high risk patients undergoing allo-HCT in light of recent clinical trials== %%POSTFIX%%. Using illustrative  clinical*
>%%LINK%%[[#^9pdwdmi0l3d|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^9pdwdmi0l3d


>%%
>```annotation-json
>{"created":"2022-09-16T08:19:53.061Z","updated":"2022-09-16T08:19:53.061Z","document":{"title":"blood.2022018003.pdf","link":[{"href":"urn:x-pdf:0f743528fbd87fed6d141af32defce56"},{"href":"vault:/hematology-theroy/papers/20220916/blood.2022018003.pdf"}],"documentFingerprint":"0f743528fbd87fed6d141af32defce56"},"uri":"vault:/hematology-theroy/papers/20220916/blood.2022018003.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220916/blood.2022018003.pdf","selector":[{"type":"TextPositionSelector","start":5494,"end":5869},{"type":"TextQuoteSelector","exact":"Ongoing clinical trials testing virus-specific  cellular  therapies,  both  single  and  multi-target,  as  well  as  new  vaccines  are presented.  To  guide  clinical  decision  making,  the  authors  provide  risk-adapted recommendations for prevention and treatment of viral reactivation based on clinical practice at three US Medical Centers with high allo-HCT activity.","prefix":"ovirus and BK virus infections. ","suffix":"   This \"How I treat\" series hig"}]}]}
>```
>%%
>*%%PREFIX%%ovirus and BK virus infections.%%HIGHLIGHT%% ==Ongoing clinical trials testing virus-specific  cellular  therapies,  both  single  and  multi-target,  as  well  as  new  vaccines  are presented.  To  guide  clinical  decision  making,  the  authors  provide  risk-adapted recommendations for prevention and treatment of viral reactivation based on clinical practice at three US Medical Centers with high allo-HCT activity.== %%POSTFIX%%This "How I treat" series hig*
>%%LINK%%[[#^q7lc1y0io4q|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^q7lc1y0io4q
